Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 11, 2016 - Issue 1
Submit an article Journal homepage
3,142
Views
20
CrossRef citations to date
0
Altmetric
Theme: Diabetes - Drug Profiles

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes

Stephen CL GoughOxford Centre for Diabetes Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, Churchill Hospital, Headington, Oxford, UKCorrespondence[email protected]
,
Rajeev JainEndocrinology, Aurora Advanced Healthcare, Milwaukee, WI, USA
&
Vincent C WooDepartment of Endocrinology and Metabolism, University of Manitoba, Winnipeg, MB, Canada
Pages 7-19 | Published online: 18 Nov 2015

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Michael Dempsey, Michelle Mocarski, Jakob Langer & Barnaby Hunt. (2018) Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US. Journal of Medical Economics 21:11, pages 1110-1118.
Read now
B. Hunt, M. Mocarski, W. J. Valentine & J. Langer. (2017) Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA. Journal of Medical Economics 20:7, pages 663-670.
Read now

Articles from other publishers (18)

Ziqi Zhang, Qiling Zhang, Ying Tan, Yu Chen, Xiqiao Zhou, Su Liu & Jiangyi Yu. (2023) GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. Frontiers in Endocrinology 14.
Crossref
Hernando Vargas-Uricoechea, Juan Pablo Frias & Hernando David Vargas-Sierra. (2023) Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials. Review of Diabetic Studies 19:1, pages 14-27.
Crossref
Jinhua Zhang, Mengjia Zhao, Yufeng He & Yuanzhen Dong. (2022) Hectogram‐scale synthesis of [Aib 8 , Arg 34 ]‐GLP‐1 (7–37) by liquid‐phase fragment condensation . Journal of Peptide Science 29:3.
Crossref
Zoltán J. Taybani, Balázs Bótyik, András Gyimesi, Mónika Katkó & Tamás Várkonyi. (2022) One‐year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes . Endocrinology, Diabetes & Metabolism 6:1.
Crossref
Eman A. Abdelwaly, Abeer A. Mohamed, Amira M. El-Kosasy & Miriam F. Ayad. (2021) A comprehensive stability assessment of insulin degludec using New customized validated RP-HPLC and SEC-HPLC methods in an orthogonal testing protocol. Journal of Pharmaceutical and Biomedical Analysis 203, pages 114175.
Crossref
Peter Kurtzhals, Erica Nishimura, Hanne Haahr, Thomas Høeg-Jensen, Eva Johansson, Peter Madsen, Jeppe Sturis & Thomas Kjeldsen. (2021) Commemorating insulin's centennial: engineering insulin pharmacology towards physiology. Trends in Pharmacological Sciences 42:8, pages 620-639.
Crossref
Michael A. Nauck, Daniel R. Quast, Jakob Wefers & Juris J. Meier. (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism 46, pages 101102.
Crossref
Mandana Hasanzad, Negar Sarhangi, Shekoufeh Nikfar, Seyed Naser Ostad & Hamid Reza Aghaei Meybodi. (2020) A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity. Journal of Diabetes & Metabolic Disorders 19:2, pages 1863-1872.
Crossref
Joseph Tibaldi, Max E. Mercado & Jodi Strong. (2020) How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?. Clinical Diabetes 38:4, pages 339-347.
Crossref
Zoltán Taybani, Balázs Bótyik, Mónika Katkó, András Gyimesi & Tamás Várkonyi. (2019) Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes. Diabetes Therapy 10:5, pages 1869-1878.
Crossref
Srikanth Bellary, Abd A Tahrani & Anthony H Barnett. (2019) IDegLira: combining efficacy, durability, and convenience?. The Lancet Diabetes & Endocrinology 7:8, pages 584-585.
Crossref
Ji Chun, Jodi Strong & Scott Urquhart. (2019) Insulin Initiation and Titration in Patients With Type 2 Diabetes. Diabetes Spectrum 32:2, pages 104-111.
Crossref
John M. Beals, Michael R. DeFelippis, Chad D. Paavola, David P. Allen, Ashish Garg & D. Bruce Baldwin. 2019. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology 403 427 .
Dimitrios Sfairopoulos, Stavros Liatis, Stelios Tigas & Evangelos Liberopoulos. (2018) Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones 17:3, pages 333-350.
Crossref
Åsa Ericsson, Divina Glah, Maria Lorenzi, Jeroen P. Jansen & Adam Fridhammar. (2018) Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. PLOS ONE 13:2, pages e0191953.
Crossref
Judy Crespi Lofton. (2017) Beyond oral antidiabetics: Insulin therapy options and combinations. Pharmacy Today 23:6, pages 53-65.
Crossref
Morten Schlein. (2016) Insulin Formulation Characterization—the Thioflavin T Assays. The AAPS Journal 19:2, pages 397-408.
Crossref
Juan José Gorgojo Martínez. (2016) Importancia del peso en el control del paciente con diabetes mellitus tipo 2: hacia una visión adipocéntrica del abordaje de la diabetes. Medicina Clínica 147, pages 8-16.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.